Multiple Sclerosis & Neuroimmunology Trials

As part of an academic medical center, the Division of Multiple Sclerosis & Neuroimmunology at Northwestern University Feinberg School of Medicine aims to improve human health through scientific research. Clinical trials test or study drugs, surgical procedures, medical devices or interventions with human subjects. They look to determine their safety and effectiveness in relation to treating specific diseases. Clinical trials are part of clinical research and are at the heart of all medical advances.

The following list includes all the active multiple sclerosis and neuroimmunology clinical trials.

Title: Ublituximab (Briumvi) for Early forms of Relapsing Multiple Sclerosis

Principal Investigator: Farrah Mateen, MD, PhD

Title: AMS05: Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis

Principal Investigator: Farrah Mateen, MD, PhD

Title: People with Multiple Sclerosis treated with Ocrelizumab and GLP-1 agonists

Principal Investigator: Farrah Mateen, MD, PhD

Title: NN111 ExTINGUISH: A Phase-2B, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Encephalitis and Assess Markers of Disease

Principal Investigator: Elena Grebenciucova, MD

Title: BEAT – MS: A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis

Principal Investigator: Bruce Cohen, MD

Title: NMOSD-750: CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Principal Investigator: Roumen Balabanov, MD

Search Studies

Trials
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis The goal of this study is to understand the safety and tolerability of Ublituximab (Briumvi) in individuals with early relapsing MS. We also want to measure changes in a blood biomarker called neurofilament light chain, before and after treatment.… The goal of this study is to understand the safety and tolerability of Ublituximab (Briumvi) in individuals with early relapsing MS. We also want to measure changes in a blood biomarker called neurofilament light chain, before and after treatment. Eligibility Criteria Inclusion Diagnosed with Multiple Sclerosis as confirmed by a neurologist in the past <5 years, Adults age 18-70 years, Able to provide consent, Brain MRI available, Planning to start Ublituximab for the treatment of relapsing MS Exclusion: Prior exposure to; Mavenclad Lemtrada Cyclophosphamide Stem cell transplant or related bone marrow suppressive treatment Other B-cell depleting agent including: Ocrelizumab Rituximab Ofatumumab Inebilizumab. - Current clinical trial participant, - Unable to speak a language for which translation can be found at Northwestern, - Unclear documentation of MS information, - Major surgery in the past 6 months, - History of life-threatening infusion reactions to Ublituximab or prior anti-CD20 therapy, - Active hepatitis B virus (HBV), - Receipt of any live of live-attenuated vaccines within 4 weeks, - Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, etc.), - Unwilling to undergo blood draws, - Unable to access Ublituximab through clinical coverage throughout the full 96-week treatment study period, - Unable to complete the study activities for any reason as deemed by the study investigator. Principal Investigator Mateen, Farrah Jasmine Location(s) Map it 675 N. St. Clair St. Suite 20 100 Chicago, IL Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100 Chicago, IL ClinicalTrials.gov IdentifierNCT07225361IRB number STU00224712 More Info Keywords Multiple sclerosis MS RRMS Relapse remitting multiple sclerosis Ublituximab Briumvi Relapsing Multiple Sclerosis Email Enkhtsetseg, Nomin Phone 312 503 5298 Copy Study URL to Clipboard Copy

Trials

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

The goal of this study is to understand the safety and tolerability of Ublituximab (Briumvi) in individuals with early relapsing MS. We also want to measure changes in a blood biomarker called neurofilament light chain, before and after treatment.…

Eligibility Criteria

Inclusion

Diagnosed with Multiple Sclerosis as confirmed by a neurologist in the past <5 years,
Adults age 18-70 years,
Able to provide consent,
Brain MRI available,
Planning to start Ublituximab for the treatment of relapsing MS

Exclusion:

Prior exposure to;
Mavenclad
Lemtrada
Cyclophosphamide
Stem cell transplant or related bone marrow suppressive treatment
Other B-cell depleting agent including:
Ocrelizumab
Rituximab
Ofatumumab
Inebilizumab.

- Current clinical trial participant,

- Unable to speak a language for which translation can be found at Northwestern,

- Unclear documentation of MS information,

- Major surgery in the past 6 months,

- History of life-threatening infusion reactions to Ublituximab or prior anti-CD20 therapy,

- Active hepatitis B virus (HBV),

- Receipt of any live of live-attenuated vaccines within 4 weeks,

- Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, etc.),

- Unwilling to undergo blood draws,

- Unable to access Ublituximab through clinical coverage throughout the full 96-week treatment study period,

- Unable to complete the study activities for any reason as deemed by the study investigator.

Principal Investigator

Mateen, Farrah Jasmine

Location(s)

Map it 675 N. St. Clair St. Suite 20 100
Chicago, IL
Map it 259 E. Erie St. Lavin Pavillion, Suite 19 100
Chicago, IL

ClinicalTrials.gov IdentifierNCT07225361IRB number STU00224712

More Info

Keywords Multiple sclerosis MS RRMS Relapse remitting multiple sclerosis Ublituximab Briumvi Relapsing Multiple Sclerosis

Email Enkhtsetseg, Nomin Phone 312 503 5298

Copy Study URL to Clipboard Copy